BR112017001310A2 - coronavírus - Google Patents

coronavírus

Info

Publication number
BR112017001310A2
BR112017001310A2 BR112017001310-0A BR112017001310A BR112017001310A2 BR 112017001310 A2 BR112017001310 A2 BR 112017001310A2 BR 112017001310 A BR112017001310 A BR 112017001310A BR 112017001310 A2 BR112017001310 A2 BR 112017001310A2
Authority
BR
Brazil
Prior art keywords
nsp
coronavirus
vaccine
mutation
proteins
Prior art date
Application number
BR112017001310-0A
Other languages
English (en)
Other versions
BR112017001310B1 (pt
Inventor
Bickerton Erica
Keep Sarah
Britton Paul
Original Assignee
The Pirbright Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017001310(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Pirbright Institute filed Critical The Pirbright Institute
Publication of BR112017001310A2 publication Critical patent/BR112017001310A2/pt
Publication of BR112017001310B1 publication Critical patent/BR112017001310B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção fornece um coronavírus atenuado vivo compreendendo um gene replicase variante que codifica poliproteínas compreendendo uma mutação em uma ou mais das proteínas não estruturais (nsp)-10, nsp-14, nsp-15 ou nsp-16. o coronavírus pode ser utilizado como uma vacina para tratar e / ou prevenir uma doença, tal como a bronquite infecciosa, em um indivíduo.
BR112017001310-0A 2014-07-23 2015-07-23 Coronavírus BR112017001310B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1413020.7A GB201413020D0 (en) 2014-07-23 2014-07-23 Coronavirus
GB1413020.7 2014-07-23
GB2016012793 2016-01-28

Publications (2)

Publication Number Publication Date
BR112017001310A2 true BR112017001310A2 (pt) 2018-04-17
BR112017001310B1 BR112017001310B1 (pt) 2022-06-28

Family

ID=51494985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001310-0A BR112017001310B1 (pt) 2014-07-23 2015-07-23 Coronavírus

Country Status (17)

Country Link
US (1) US10130701B2 (pt)
EP (2) EP3172319B1 (pt)
JP (1) JP6712268B2 (pt)
KR (1) KR20170032441A (pt)
CN (1) CN106536723A (pt)
AU (1) AU2015293633B2 (pt)
BR (1) BR112017001310B1 (pt)
CA (1) CA2953677C (pt)
DK (1) DK3172319T3 (pt)
ES (1) ES2764275T3 (pt)
GB (1) GB201413020D0 (pt)
HU (1) HUE047953T2 (pt)
IL (1) IL249340A0 (pt)
MX (1) MX2016016722A (pt)
PL (1) PL3172319T3 (pt)
PT (1) PT3172319T (pt)
WO (1) WO2016012793A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684667B2 (en) * 2017-03-03 2023-06-27 Loyola University Of Chicago Coronaviruses, vaccines comprising the same, and methods for preventing disease
BR112021008390A2 (pt) * 2018-10-31 2021-09-28 Boehringer Ingelheim Vetmedica Gmbh Vacina de ibv h52 com proteína da espícula heteróloga
KR102119875B1 (ko) * 2019-03-19 2020-06-05 한국화학연구원 한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도
EP3966318A1 (en) * 2019-05-10 2022-03-16 Boehringer Ingelheim Vetmedica GmbH Attenuated ibv with extended cell culture and tissue tropism
CN111254155A (zh) * 2020-01-25 2020-06-09 王跃驹 一种植物作为宿主表达病毒疫苗的方法
KR20220151168A (ko) 2020-02-09 2022-11-14 엔엘씨 파르마 엘티디 Sars-cov-2에 대한 신속한 검출 테스트
CN115884785A (zh) * 2020-03-23 2023-03-31 芝加哥罗约拉大学 冠状病毒疫苗组合物及其使用方法
WO2021203236A1 (zh) * 2020-04-07 2021-10-14 四川骋誉生物制品有限公司 用于预防covid-19的蝙蝠源性冠状病毒疫苗
BR112022026899A2 (pt) 2020-07-20 2023-01-24 Enanta Pharm Inc Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
JP2024004496A (ja) * 2020-10-14 2024-01-17 一般財団法人阪大微生物病研究会 ノックアウトコロナウイルス
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN112592905B (zh) * 2020-12-28 2023-07-28 广州达安基因股份有限公司 用于新型冠状病毒检测的dna聚合酶混合物
CN114751964B (zh) * 2020-12-29 2024-03-08 苏州方舟生物科技有限公司 β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
CN113308440B (zh) * 2021-05-26 2023-04-28 武汉大学 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
EP4404946A1 (en) * 2021-09-22 2024-07-31 BiomEdit, LLC Methods of inhibiting diseases caused by respiratory viruses
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078203A2 (en) 2003-03-03 2004-09-16 Akzo Nobel N.V. Infectious bronchitis virus with an altered spike gene
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EP1533370A1 (en) * 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
CN100413537C (zh) * 2004-01-29 2008-08-27 国家人类基因组南方研究中心 Sars冠状病毒全病毒疫苗
US7452542B2 (en) * 2004-05-21 2008-11-18 Vanderbilt University Live attenuated coronavirus vaccines
WO2007078203A1 (en) 2006-01-03 2007-07-12 Norwex Holding As Anti-bacterial micro-fibre and production thereof
GB0911794D0 (en) 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
CN102851257A (zh) * 2012-08-27 2013-01-02 上海启盛生物科技有限公司 一种鸡传染性支气管炎病毒减毒疫苗株及其应用
CN103397002A (zh) * 2013-08-07 2013-11-20 广东温氏食品集团股份有限公司 禽传染性支气管炎病毒的致弱方法

Also Published As

Publication number Publication date
ES2764275T3 (es) 2020-06-02
GB201413020D0 (en) 2014-09-03
PT3172319T (pt) 2020-01-14
HUE047953T2 (hu) 2020-05-28
WO2016012793A1 (en) 2016-01-28
EP3172319B1 (en) 2019-11-20
CN106536723A (zh) 2017-03-22
EP3172319A1 (en) 2017-05-31
IL249340A0 (en) 2017-02-28
US10130701B2 (en) 2018-11-20
PL3172319T3 (pl) 2020-06-29
US20170216427A1 (en) 2017-08-03
CA2953677C (en) 2023-09-26
AU2015293633B2 (en) 2021-04-08
AU2015293633A1 (en) 2016-12-15
MX2016016722A (es) 2017-04-13
JP2017522907A (ja) 2017-08-17
EP3656856A1 (en) 2020-05-27
KR20170032441A (ko) 2017-03-22
JP6712268B2 (ja) 2020-06-17
DK3172319T3 (da) 2020-02-03
CA2953677A1 (en) 2016-01-28
EP3656856B1 (en) 2021-10-20
BR112017001310B1 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
BR112017001310A2 (pt) coronavírus
CL2018001056A1 (es) Vacuna contra el virus herpes simplex
MX2018007627A (es) Vacuna contra el virus del zika.
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112016024644A2 (pt) vacinas de ácido nucleico
PE20180260A1 (es) Metodos y kits para tratar la depresion
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112014013276A2 (pt) vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
EA201591761A1 (ru) Композиции на основе наночастиц
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CL2016000358A1 (es) Vacuna para adenovirus aviar
BR112018015453A2 (pt) vírus atenuado da bronquite infecciosa
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2021010060A (es) Produccion de virus en huevos aviares.
BR112017015789A2 (pt) vacina de vírus da influenza suína bivalente
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112016024176A2 (pt) composições para tratamento bucal tendo estabilidade aprimorada
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2015, OBSERVADAS AS CONDICOES LEGAIS